Welcome to our dedicated page for Corvel SEC filings (Ticker: CRVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CorVel Corporation's SEC filings document the company's public-company reporting for a technology-enabled risk management business serving workers' compensation and health, auto, and liability programs. Recent 8-K filings furnish quarterly financial results through Item 2.02 disclosures and related earnings press releases.
CorVel's proxy and annual meeting filings cover stockholder voting matters, director elections, auditor ratification, and governance procedures. The filings also identify the company's common stock, par value $0.0001 per share, traded under CRVL on the Nasdaq Global Select Market, tying its governance record to its listed equity security.
CorVel Corp (CRVL) disclosed that Chief Information Officer Maxim Shishin received a performance-based non-qualified stock option grant. The award covers 4,000 options with an exercise price of $75.36, granted on 11/06/2025 and expiring on 11/06/2030. Vesting is tied to achieving certain performance criteria relating to earnings growth. The filing lists the ownership of the derivative securities as direct.
CorVel (CRVL) reported an insider equity grant. The company’s EVP of Risk Management Services received a non-qualified stock option for 4,000 shares at an exercise price of $75.36 on 11/06/2025, coded “A” for award. The option expires on 11/06/2030 and vests based on achieving performance criteria related to earnings growth. Following the grant, 4,000 derivative securities were beneficially owned, held directly.
CorVel Corporation filed a Form S-8 registering 1,775,459 shares of common stock for issuance under the CorVel Corporation 2025 Stock Incentive Plan. The plan was approved by stockholders on August 7, 2025. This registration supports equity-based compensation, allowing the company to grant options and other awards to employees, directors, and eligible participants under the plan.
Form S-8 registrations are administrative and do not, by themselves, represent a capital raise or a public sale. Instead, they make plan shares available for future grants consistent with the plan’s terms and applicable securities laws.
CorVel Corporation reported stronger quarterly results for the three months ended September 30, 2025. Revenue reached $239,643,000, up 7% year over year, as network solutions activity expanded with existing customers. Net income was $27,906,000 and diluted EPS was $0.54, compared with $0.45 a year ago.
Profitability improved: gross margin rose to 24.3% from 22.6%, while general and administrative costs held near 9% of revenue. Segment mix was 62.9% patient management ($150,795,000) and 37.1% network solutions ($88,848,000). Operating cash flow for the first six months totaled $80,035,000, supporting cash and equivalents of $207,453,000.
The company continued buybacks, repurchasing 143,774 shares for approximately $12.8 million in the quarter and 230,879 shares for $22.5 million year-to-date. Shares outstanding were 51,293,374 as of September 30, 2025. Management also noted a recent technology asset acquisition to enhance bill review capabilities.
CorVel Corporation issued a press release announcing its financial results for the three and six months ended September 30, 2025, and furnished it as Exhibit 99.1.
The information was furnished to the SEC and is not deemed filed under the Exchange Act. CorVel’s common stock (CRVL) is listed on the Nasdaq Global Select Market.
Jennifer Yoss, Vice President of Accounting at CorVel Corp (CRVL), reported a purchase of 35 shares of CorVel common stock on 09/30/2025 at a price of $73.549 per share. The shares were acquired under the issuer's Employee Stock Purchase Plan in a transaction exempt under SEC Rule 16b-3(c). Following the purchase, Ms. Yoss beneficially owns 2,123 shares, held directly. The Form 4 was signed on behalf of the reporting person by Sharon O'Connor on 10/01/2025.
Michael G. Combs, CEO & President of CorVel Corp (CRVL), reported a purchase of 44 shares of the issuer's common stock on 09/30/2025 at a per-share price of $73.549. The acquisition was made under the company's Employee Stock Purchase Plan and is noted as exempt under SEC Rule 16b-3(c). After the transaction, Mr. Combs beneficially owned 44,325 shares. The Form 4 was submitted as a single-person filing and signed on behalf of the reporting person on 10/01/2025.
Mark E. Bertels, Executive Vice President - Risk Management Services at CorVel Corp (CRVL), reported an open-market acquisition under the companys Employee Stock Purchase Plan on 09/30/2025. The filing shows 8 shares acquired at a price of $73.549 per share, bringing his direct beneficial ownership to 2,594 shares. The purchase is described as exempt under SEC Rule 16b-3(c). The Form 4 was signed on behalf of Mr. Bertels by Sharon O'Connor on 10/01/2025.
CorVel Corporation insider filing reports a proposed Rule 144 sale of 18,000 common shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $1,580,823.00. The filer states those shares were acquired by stock option exercise on 09/11/2025 and paid for in cash the same day. The filing also discloses that the same person sold 12,000 shares on 08/20/2025 for gross proceeds of $1,069,975.20. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
CorVel Corp (CRVL) Form 4 filing: Corstar Holdings Inc. reported a sale of 70,000 shares of CorVel common stock on 09/08/2025 at a price of $91.46 per share, leaving 18,742,108 shares beneficially owned following the transaction. The filing indicates the sale was made under a Rule 10b5-1 trading plan adopted May 28, 2025. The Form 4 is signed on behalf of the reporting entity and lists the reporting person as a director and 10% owner. The transaction is recorded as a direct disposition of common stock and no derivative transactions are reported.